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Abstract
Objective: To investigate the association between metabolic risk factors (individually and in combination) and risk of
gallbladder cancer (GBC).
Methods: The metabolic syndrome and cancer project (Me-Can) includes cohorts from Norway, Austria, and Sweden with
data on 578,700 men and women. We used Cox proportional hazard regression models to calculate relative risks of GBC by
body mass index (BMI), blood pressure, and plasma levels of glucose, cholesterol, and triglycerides as continuous
standardised variables and their standardised sum of metabolic syndrome (MetS) z-score. The risk estimates were corrected
for random error in measurements.
Results: During an average follow-up of 12.0 years (SD = 7.8), 184 primary gallbladder cancers were diagnosed. Relative risk
of gallbladder cancer per unit increment of z-score adjusted for age, smoking status and BMI (except for BMI itself) and
stratified by birth year, sex and sub-cohorts, was for BMI 1.31 (95% confidence interval 1.11, 1.57) and blood glucose 1.76
(1.10, 2.85). Further analysis showed that the effect of BMI on GBC risk is larger among women in the premenopausal age
group (1.84 (1.23, 2.78)) compared to those in the postmenopausal age group (1.29 (0.93, 1.79)). For the other metabolic
factors no significant association was found (mid blood pressure 0.96 (0.71, 1.31), cholesterol 0.84 (0.66, 1.06) and serum
triglycerides 1.16 (0.82, 1.64)). The relative risk per one unit increment of the MetS z-score was 1.37 (1.07, 1.73).
Conclusion: This study showed that increasing BMI and impaired glucose metabolism pose a possible risk for gallbladder
cancer. Beyond the individual factors, the results also showed that the metabolic syndrome as an entity presents a risk
constellation for the occurrence of gallbladder cancer.
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Introduction
Primary gallbladder cancer (GBC) is the most common biliary
tract tumour and the sixth most common cancer affecting the
gastrointestinal tract [1,2]. It is a disease typically characterised by
late diagnosis and poor outcome with a five year survival of only
about 32% [3]. Although the presence of gallstones is considered
to be an important risk factor, several other unidentified factors
may be important in the development of gallbladder carcinoma.
About 10 to 25% of patients with this disease do not have
associated cholelithiasis and only a small proportion (1 to 3%) of
patients that do have gallstones actually develop cancer [4].
Metabolic syndrome (MetS) is a constellation of factors related
to insulin resistance including obesity, impaired glucose tolerance,
dyslipidaemia and hypertension with varying definitions [5]. It has
consistently been associated with an increased risk of cardiovas-
cular diseases and diabetes type 2 [6,7], and recently with risk
of cancer at some sites like colorectal, prostate and liver cancers
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[8–13]. There is little data on the association between the MetS
and risk of GBC, for separate as well as for a combination of MetS
factors [10–17]. Most of these studies are either based on a single
specific metabolic factor like obesity or diabetes [10–12,14], apply
an unfavourable proxy for MetS or they are non-prospective in
nature [13–17]. To our knowledge this is the largest prospective
study that assessed MetS and separate metabolic risk factors like
serum lipids and blood pressure in association with gallbladder
carcinoma.
In this large study of 578,700 participants, we aimed to
investigate the association between metabolic risk factors, individ-
ually and in combination, and the risk of gallbladder cancer,
taking random error into account.
Materials and Methods
Detailed description of materials and methods of this study has
been presented previously [18,19].
Study Population and Measurements
The study population comes from the Metabolic syndrome and
Cancer project (Me-Can) which includes cohorts with 578,700
participants from Norway, Austria and Sweden. In these cohorts,
health examinations data have been collected on height, weight,
blood pressure, blood levels of glucose, total cholesterol, triglyc-
erides, and smoking status. Time period of data collection spanned
from 1972 to 2006. A detailed description of Me-Can and
inclusion criteria for participants in this study has been previously
described [18].
Follow-up and Endpoints
Linkages have been performed with cause of death and vital
status registries of the respective countries in order to identify those
cases with incident gallbladder cancer (ICD-7): 155.1). Endpoints
for the study were set at the date of the first cancer diagnosis,
emigration, death, or December 31, 2003 (Austria), 2005 (Norway)
and 2006 (Sweden).
Statistical Analysis
The statistical analysis of this study is similar to a previously
published study by the same study group [19]. In brief, Cox
proportional hazards regression models, with age as the time
variable, were fitted to obtain hazard ratios, denoted as relative
risks (RRs), of primary GBC incidence with 95% confidence
intervals (95% CI). We did our main analyses with both sexes
combined as there was no significant interaction between sex and
each of the MetS factors. As in the previous publications of Me-
Can studies, analyses were undertaken with exposures as quintiles,
standardized z-score continuous variables as well as bi-categorical
values using the WHO defined cut-off points of the determinant
variables.
Quintile Analysis
Quintile cut-off points for the exposure variables were
calculated within each cohort and sex. For glucose, cholesterol
and triglycerides, cut-offs were additionally stratified by fasting
time before blood sampling (.8 hours, fasting or #8 hours, non-
fasting). The models were further stratified for the seven cohorts,
sex and year of birth (five categories: #1929, 1930–39, 1940–49,
1950–59, and $1960), and adjusted for age, smoking status (three
categories: never, former and current smokers) and for BMI where
appropriate. The lowest quintile was used as a reference. Mean
levels within the quintiles of exposure variables were used to test
for linear trend.
Standardized z-score Analysis
In addition to the quintile analysis, we also performed statistical
tests with the exposures on a continuous scale. Standardized scores
let each determinant to be investigated in the same scale making a
uniform comparison possible. We transformed the existing values
to standardised variables (z-scores), with zero as mean and one as
standard deviation (z = (x - m)/s). As in the quintile analysis, the
transformation is stratified by cohort, sex, and fasting time.
Skewed variables (glucose and triglycerides) were logarithmically
transformed prior to standardisation. Metabolic syndrome (MetS)
score was constructed by adding the individual z-scores, and
further standardization of the resulting sum. The adjustments and
the stratifications in the z-score analysis are the same as in the
quintile analysis.
Analysis by WHO Standards
We also estimated risks in two categories according to cut-offs
defined by WHO as follows: overweight (BMI 25–,30 kg/m2),
obesity (BMI$30 kg/m2), hypertension (systolic blood pressure $
140 mmHg and/or diastolic blood pressure $90 mmHg), im-
paired glucose tolerance (fasting glucose 6.0–6.9 mmol/l), diabetes
(fasting glucose $7.0 mmol/l), hypertriglyceridemia (fasting tri-
glycerides $1.7 mmol/l), and hypercholesterolemia (fasting total
cholesterol $6.2 mmol/l). For blood glucose and lipids only those
individuals who had fasted .8 hours prior to blood draw were
included [20–22]. The same adjustment and stratification scheme
was used as in the models with quintile and continuous exposure
variables.
Random Errors
All risk estimates were adjusted for random error in exposure
measurements, based on data on repeated measurements from
133,820 participants with a total of 406,364 observations. These
data were used to estimate regression dilution ratios (RDR) or
regression calibration (RC) based on linear mixed effect models
[23–25]. RRs derived from quintile and standardised z-score
analyses were then corrected by dividing the regression coefficient
in the Cox model by the estimated regression dilution ratio (RDR)
of exposure. RRs from the z-scores analyses which adjusted for all
individual metabolic factors in one model were corrected by
regression calibration.
Further Analytic Considerations
Since reproductive factors are important risk factor for
gallbladder diseases in women [3,4], we did additional risk
estimation separately for women ,50 years of age (n = 214,572)
and $50 years of age (n = 72,748) using this age-cut-off as a proxy
for pre- and postmenopausal status, respectively.
Our main analyses excluded the first year after baseline
measurements in order to account for possible reverse causality
between exposures and event. We consolidated the issue by
performing further lag-time analyses that excluded the first 3 years
of follow-up.
Statistical analyses were performed in Stata (version 10.0,
StataCorp LP, College Station, Texas) and R (version 2.7.2, used
for random error correction).
Ethics
The study was approved by The Research Review Board of
Umea˚, Sweden, the Regional Committee for Medical and Health
Research Ethics, Southeast Norway and the Ethikkommission of
the Land Vorarlberg, Austria. Participants from Sweden and
Austria provided written informed consent to participate in this
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study. In Norway, the participants were invited to come to the
health survey and a questionnaire was sent together with the
invitation. An attendance to the health examination where the
participants delivered their filled in questionnaire, has been
accepted by the Data Inspectorate as an informed consent, but
not a written consent. Written consent was obtained from 1994
onwards.
Results
Mean age at baseline was 43.9 years (SD = 11.1) in men and
44.1 years (SD = 12.3) in women (Table 1). Men were followed on
average for 12.8 years (SD = 8.6) and women for 11.3 years
(SD = 6.8). The prevalence of overweight or obesity (BMI 25 kg/
m2 or higher) was 55% in men and 41% in women. Among
participants with a follow-up time longer than one year 91 men
and 93 women were diagnosed with primary GBC. Mean ages at
the time of cancer diagnosis were 62.9 years (SD = 8.7) in men and
65.5 years (SD = 10.9) in women.
In quintile analysis, BMI and blood glucose were significantly
associated with increases in risk of GBC (Table 2). The relative risk
for the highest versus lowest quintile in models, adjusted for age,
smoking status and BMI (except for BMI itself), stratified by birth
years, sex and cohorts, and corrected for RDR, was 1.94 (95% CI
1.08, 3.51) for BMI and 5.38 (1.11, 26.5) for blood glucose.
In multivariable adjusted analyses of z-scores, significant
associations were found for a unit z-score increment of BMI
(1.31 (1.11, 1.57)) and blood glucose (1.76 (1.10, 2.85)). The
relative risk per unit increment of the MetS z-score was 1.37 (1.07,
1.73). In a further analysis where all the metabolic risk factors were
calibrated and adjusted for each other, the significant association
persisted only for BMI. No statistically significant association with
GBC was observed for blood pressure, cholesterol and triglycerides
(Table 3).
There were no statistically significant interactions when testing
effect modification of metabolic factors on GBC risk. Notable were
however varying associations of BMI with GBC by age. The
relative risk per unit increment of BMI was 1.84 (1.23, 2.78) in
premenopausal (n = 32) and 1.29 (0.93, 1.79) (n = 61) in postmen-
opausal ($50 years of age) women.
In analyses of the exposures in dichotomised categories
according to the WHO classification of risk factors (Table 4),
increases in risk were found for individuals with overweight (BMI
above versus below 25 kg/m2) and individuals with impaired
glucose metabolism (fasting blood glucose above versus below
6.0 mmol/l) with a relative risk of 1.52 (1.12, 2.10) and 1.62 (1.00,
2.62), respectively. These analyses were restricted to 278,300
individuals with .8 h fasting time.
Supplementary tables S1–S4 show sub-analyses of risks for men
and women separately. Sex-specific risk estimates were similar to
the combined analyses with some exceptions. Notably, the
magnitude of the observed association between BMI and GBC
was stronger and statistically significant in women.
Discussion
In this large cohort study comprising of 578,700 men and
women, a composite metabolic syndrome score, based on BMI,
blood pressure, and circulating concentrations of glucose, total
cholesterol and triglycerides, was significantly associated with
GBC risk. Further analysis of single metabolic risk factors revealed
that BMI and glucose were significantly associated with increased
risk of GBC.
Table 1. Baseline characteristics of study participants in the
Metabolic syndrome and Cancer project (Me-Can) including
the first year of follow-up (n = 578,700).
Cohort
(year of baseline
measurement),
n participants (%) Men Women
Oslo (1972–73) 16,760 (6)
NCS (1974–83) 25,952 (9) 25,072 (9)
CONOR (1995–2003) 52,181 (18) 57,687 (20)
40-y (1994–99) 60,676 (21) 68,211 (23)
VHM&PP (1988–2002) 73,213 (25) 86,671 (30)
VIP (1985–2005) 38,843 (13) 40,669 (14)
MPP (1974–92) 22,241 (8) 10,524 (4)
Total (1972–2005) 289,866 288,834
Baseline age, years
Mean (SD) 43.9 (11.1) 44.1 (12.3)
Categories, n (%)
,30 27,244 (9) 33,067 (11)
30– ,45 157,145 (54) 154,462 (54)
45– ,60 76,623 (27) 67,689 (23)
60- 28,854 (10) 33,616 (12)
Fasting time, hours, n (%)1
,4 120,510 (41) 122,319 (42)
4–8 30,769 (11) 26,802 (9)
.8 138,587 (48) 139,713 (49)
Smoking status, n (%)
Never smoker 113,496 (39) 144,815 (50)
Ex-smoker 86,086 (30) 72,600 (25)
Current smoker 89,419 (31) 70,721 (25)
Missing 865 (0) 698 (0)
BMI, kg/m2
Mean (SD) 25.7 (3.5) 24.9 (4.4)
Categories, n (%)
,25 131,167 (45) 170,535 (59)
25– ,30 127,846 (44) 82,869 (29)
30– 30,853 (11) 35,430 (12)
Follow-up, years
Mean (SD) 12.8 (8.6) 11.3 (6.8)
Categories, n (%)
,5 36,755 (13) 35,451 (12)
5 – ,15 178,968 (62) 199,151 (69)
15 – ,25 24,971 (8) 29,751 (10)
25– 48,172 (17) 24,481 (9)
1Proportion of participants with a fasting time .8 h: 5% in the Norwegian
cohorts, 90% in the VIP, and 100% in the VHM&PP and MPP.
Abbreviations: Oslo =Oslo study I; NCS =Norwegian Counties Study;
CONOR=Cohort of Norway; 40-y = Age 40-programme; VHM&PP= Vorarlberg
Heath Monitoring and Prevention Programme; VIP = Va¨sterbotten Intervention
Project; MPP=Malmo¨ Preventive Project; SD = standard deviation; BMI = body
mass index.
doi:10.1371/journal.pone.0089368.t001
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Strengths and Limitations
The main strengths of our study are the large number of
participants and its prospective design. We used data from
population-based surveys in three countries, with almost complete
coverage of data for measured exposure factors. The large number
of repeated measurements within the study population allowed us
to adjust for random error in the individual MetS factors. We also
used high quality national registers in Austria, Norway, and
Sweden for the follow-up regarding cancer diagnoses [26–28].
An important limitation of the study is the lack of data on
gallstone status - a well established risk factor for GBC [3,4,29].
Gallstone status is also highly linked to the presence of metabolic
risk factors like obesity, diabetes and dyslipidemia [17,30]. With
this constellation we cannot exclude the possible mechanistic role
of gallstones in the association between metabolic risk factors and
GBC as has been elegantly presented in previous prospective
studies on obesity and diabetes [31,32] as well as case-control
studies [15–16]. However, it is also evident that a considerable
proportion of individuals with GBC show no sign of cholelithiasis
[3,4], signifying the presence of other factors that may play
important role gallbladder carcinogenesis.
Another limitation of the study is the noticeably small number
of events, despite the large number participants, which might have
Table 2. Risk of Primary gallbladder cancer in relation to
quintiles of metabolic factors (n = 575,390).
Primary gallbladder cancer (n = 184)
Mean
(SD)
n,
cases Model
2 Model3
Exposures
Quintile
level1 RR 95%CI RR 95%CI
BMI 1 20.7 (1.3) 20 1.00
(kg/m2) 2 23.0 (0.8) 26 1.12 0.58, 2.19
3 24.7 (0.8) 38 1.49 0.80, 2.76
4 26.8 (0.9) 47 1.70 0.93, 3.09
5 31.3 (2.6) 53 1.94 1.08, 3.51
P trend 0.08
Mean BP1 1 8.2 (4.9) 20 1.00 1.00
(mmHg) 2 96.9 (2.4) 27 1.37 0.48, 4.01 1.27 0.44,
3.74
3 102.7 (2.3) 41 2.11 0.77, 5.75 1.86 0.68,
5.04
4 109.8 (2.9) 35 1.02 0.36, 2.86 0.82 0.29,
2.32
5 124.5 (9.5) 60 1.81 0.68, 4.81 1.25 0.45,
3.45
P trend 0.47 0.92
Glucose 1 4.2(0.5) 31 1.00 1.00
(mmol/l) 2 4.8 (0.3) 34 2.51 0.47, 13.5 2.32 0.43,
12.7
3 5.1 (0.3) 28 1.18 0.20, 7.11 1.07 0.18,
6.33
4 5.5 (0.4) 38 3.14 0.60, 16.5 2.64 0.49,
13.9
5 6.8 (2.0) 53 7.52 1.56, 36.1 5.38 1.11,
26.5
P trend 0.01 0.04
Cholesterol 1 4.2 (0.5) 27 1.00 1.00
(mmol/l) 2 5.0 (0.3) 37 1.14 0.53, 2.47 1.11 0.52,
2.38
3 5.6 (0.3) 34 0.74 0.33, 1.61 0.70 0.32,
1.53
4 6.2 (0.3) 40 0.71 0.35, 1.53 0.66 0.31,
1.42
5 7.4 (0.8) 46 0.67 0.32, 1.46 0.62 0.29,
1.32
P trend 0.14 0.08
Triglycerides11 1 0.7 (0.2) 22 1.00 1.00
(mmol/l) 2 1.0 (0.2) 30 1.48 0.45, 4.88 1.38 0.38,
2.00
3 1.3 (0.3) 34 1.40 0.44, 4.49 1.20 0.21,
1.16
4 1.9 (0.4) 46 2.50 0.84, 7.61 1.94 0.40,
1.97
5 3.1 (1.7) 48 2.06 0.67, 6.28 2.90 0.30,
1.53
P trend 0.12 0.50
1Quintile levels grouped by cohort and sex and for glucose, cholesterol and
triglycerides further by fasting time. RRs were estimated from Cox regression
models with attained age as time scale after excluding the first year after
baseline measurement.
2RRs were adjusted for smoking status and age at baseline, stratified by cohort,
Table 3. Relative risk (95% CI) of primary gallbladder cancer,
by z-scores of metabolic factors, and of the MetS score
(n = 575,390).
Primary gallbladder cancer (n = 184)
Model1 Model2 Model3
Exposures RR 95%CI RR 95%CI RR 95%CI
BMI 1.31 1.11, 1.57 1.23 1.03, 1.46
Mean blood
pressure
1.10 0.82, 1.46 0.96 0.71, 1.31 0.97 0.82, 1.15
Glucose4 1.97 1.38, 3.22 1.76 1.10, 2.85 1.58 0.98, 2.54
Cholesterol 0.87 0.69, 1.11 0.84 0.66, 1.06 0.84 0.64, 1.10
Triglycerides4 1.14 0.98, 1.88 1.16 0.82, 1.64 1.11 0.77, 1.61
MetS 1.37 1.07, 1.73
1Relative risks were estimated from Cox regression models after excluding the
first year of follow-up after baseline measurement, with attained age as time
scale, stratified by cohort, sex and categories of birth year, adjusted for baseline
age and smoking status, and corrected for regression dilution bias by use of
regression dilution ratio (RDR); conversion into uncorrected RR = exp (log
(RR)*RDR). RDR: BMI, 0.90; mean blood pressure, 0.54; log(glucose), 0.28;
cholesterol, 0.66; log(triglycerides), 0.51.
2Additionally adjusted for BMI.
3Further adjusted for all the individual z-scores (except in MetS score analysis).
In addition, z-scores, derived from original values, were calibrated.
4Glucose and triglycerides were logarithmically transformed.
Abbreviations: CI, confidence interval; MetS, metabolic syndrome; BMI, body
mass index; RR, relative risk.
doi:10.1371/journal.pone.0089368.t003
sex and categories of birth year. RRs are corrected for regression dilution bias by
use of the regression dilution ratio (RDR); conversion into uncorrected RR = exp
(log (RR)*RDR). RDR: BMI, 0.90; mean blood pressure, 0.54; glucose, 0.28;
cholesterol, 0.66; triglycerides, 0.51. Glucose and triglycerides were
logarithmically transformed.
3RR were further adjusted for quintiles levels of BMI (except in BMI analysis).
1value missing for 1 case.
11value missing for 4 cases.
Abbreviations: RR, relative risk; SD, standard deviation; BMI, body mass index;
Mid BP, mean blood pressure; RDR, regression dilution ratio.
doi:10.1371/journal.pone.0089368.t002
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contributed to the large confidence intervals seen especially in the
quintile analyses. Lack of information on the reproductive history
[3] among women may also be a limitation. However, we did a
further risk estimation for women ,50 and $50 years of age as a
proxy for pre- and postmenopausal age groups, respectively. Our
study is also limited by lack of data on socioeconomic status as well
as some other behavioural aspects like alcohol consumption and
physical activity. Moreover we lack data on treatment history of
the abnormal metabolic factors like hypertension and dyslipidemia
which might, to some extent, have confounded our risk estimate.
For the most recent definition of the MetS [5] we lack data on
specific factors like waist circumference and high density
lipoprotein cholesterol which we had to replace with BMI and
total cholesterol respectively. Consequently we have presented our
results based on a metabolic syndrome score which we used as a
proxy for the syndrome [33].
Comparisons with the Literature
The observed significant association between metabolic syn-
drome and GBC in this study with large number of participants
and adequately long follow-up period strengthens reports by a
previous case-control study based on over 600 biliary tract cancers
which also found significant role of Mets on GBC [17]. However,
such studies may be limited by the timing of exposure and
outcome not being able to exclude reverse causality. This may
probably be the case with the lack of association between waist
circumference and risk of GBC. Such deficiencies are better dealt
with prospective studies of long follow up period. Although several
prospective studies exist on individual metabolic factors [31,32],
literatures on the association between MetS as an entity and GBC
are scarce [13]. In a previous prospective study [13] MetS was
defined as simultaneous exposure to antihypertensive, hypogly-
caemic and hypolypemic treatments which is a rather rough
approximation of MetS. Compared to ours this previous study did
not find statistically significant association between MetS and
GBC which is a rather questionable finding in the face of evident
significant association with most of the individual components.
Although several independent mechanisms are depicted to
underpin the association between obesity and cancer, the
mechanisms that link obesity with gallbladder cancer risk are
unclear [34–36]. Many studies have identified obesity as a risk to
be more pronounced in women, and suggested a possible role of
sex hormones (mainly oestrogen) in the pathogenesis of GBC
[8,13,29,36–41]. There are even indications that sex hormone
receptors exist on the tumour tissue [42]. Our results, that
increasing BMI poses greater risk mainly in younger women of
premenopausal age group, might be supportive of this mechanism.
This finding is supported by another cohort study in Norway [13].
In tumours that depend on oestrogen for their growth, like
breast and endometrial cancers, obesity is shown to be of greater
risk in postmenopausal women [43–46]. In our study, however,
the risk for GBC was higher for younger women below the age of
50. This observation might be due to chance, as we did not find a
significant interaction between age and BMI. However, if
confirmed in further studies, the clinicopathological mechanisms
may be entirely different for GBC.
Blood glucose levels were shown to be associated with incidence
of cancer overall and in several specific sites like the colon,
pancreas, liver, and endometrium in previous studies [11,28,47–
48]. Studies reporting specifically a link between GBC and blood
glucose levels are almost inexistent [28]. The association between
glucose and cancer risk in our study remained after adjustment for
major putative confounders like BMI, smoking and age, indicating
a possible causal link. However, biological mechanisms in the
association between blood glucose and cancer are poorly
understood. A large case-control study by associated with high
blood pressure, none of these studies identified blood pressure as
risk for GBC.
A case-control study on serum lipids and biliary tract cancers
including gallbladder cancer showed that compared to controls,
cases had significantly higher mean levels of serum triglyceride
(STG) [15]. However, our study, based on prospective data
analyses as well as other similar cohort studies did not confirm this
finding [48,52]. In the study by Andreotti et al serum measure-
ment took place shortly after cancer diagnosis. In this constellation
one cannot rule out a possible reverse causation due to disease
effect [53].
In conclusion, our study showed that increasing BMI and blood
glucose levels are possible risk factors for GBC. Obesity was seen
to pose a greater risk among women in the premenopausal age.
Beyond the individual factors, the results of our study show that
the metabolic syndrome as an entity presents a risk constellation
for the occurrence of gallbladder cancer. Considering the rise in
temporal trend of BMI and blood glucose levels [48,54], we would
anticipate that the incidence ofShebl et al indicated that although
diabetes could be a risk factor for gallstone formation, the
association between diabetes and GBC can be explained only
Table 4. Relative risk (95% CI) of primary gallbladder cancer
by WHO categories of metabolic factors (n = 575,390).
Exposures Relative risks (95% CI)
n,
cases Model
2 Model3
Cut-off
levels1 RR 95%CI RR 95%CI
BMI ,25 77 1.00
(kg/m2) $25 107 1.52 1.12, 2.10
Systolic BP ,140 108 1.00 1.00
(mmHg) $140 76 1.04 0.75, 1.44 0.93 0.66,
1.29
Diastolic BP ,90 123 1.00 1.00
(mmHg) $90 61 1.00 0.73, 1.37 0.96 0.74,
1.25
Fasting glucose4
(mmol/l)
,6.0 101 1.00 1.00
$6.0 23 1.80 1.12, 2.88 1.62 1.00,
2.62
Fasting total
cholesterol4
,6.2 78 1.00 1.00
(mmol/l) $6.2 46 0.90 0.62, 1.32 0.89 0.61,
1.29
Fasting triglycerides4 ,1.7 80 1.00 1.00
(mmol/l) $1.7 44 1.22 0.83, 1.80 1.09 0.73,
1.62
1Cut-off levels are according to WHO definition.
2RRs were estimated from Cox regression models with attained age as time
scale, adjusted for smoking status and age at baseline, stratified by cohort,
categories of birth year, and sex.
3RRs were further adjusted for BMI (except in BMI analysis).
4RRs were estimated only for individuals who had fasted 8 or more hours before
baseline blood sampling (n = 277,300).
Abbreviations: BMI, body mass index; BP, blood pressure; CI, confidence
interval; RR, relative risk.
doi:10.1371/journal.pone.0089368.t004
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partly by the positive association between diabetes and gallstones
[14].
The inverse association we observed between total cholesterol
and GBC in women may be largely due to preclinical effects of the
cancer on total serum cholesterol [49]. A lag-time sub-analysis
excluding 3 years of follow up after baseline measurement, rendered
the association non-significant although the direction of association
persisted. This was also shown in another recently published Me-
Can study on total serum cholesterol and cancer [50].
Studies on the association between blood pressure and GBC
incidence are scarce [48,51]. Although it was shown that several
cancer sites might be significantly GBC might also increase.
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